Merck-backed MilliporeSigma completed the acquisition of Mirus Bio from KKR-backed Gamma Biosciences for $600m.

Merck-backed MilliporeSigma, a life sciences company, completed the acquisition of Mirus Bio, a transfection reagents, electroporation solutions and related products company, from KKR-backed Gamma Biosciences, a life sciences tools platform, for $600m. "Novel modalities like cell and gene therapies offer tremendous potential for bringing new curative treatments to patients. Mirus Bio’s advanced technology, combined with our bioprocessing expertise and broad portfolio, will enable us to deliver integrated solutions across the viral vector value chain and help meet the growing demand for these life-saving therapies,” Sebastian Arana, Merck Head of Process Solutions.